Exploration of the Potential Association Between GLP-1 Receptor Agonists and Suicidal or Self-injurious Behaviors: a Pharmacovigilance Study Based on the FDA Adverse Event Reporting System Database

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2024 Feb 14

PMID 38355513

Authors

Jianxing Zhou

You Zheng

Baohua Xu

Songjun Long

Li-E Zhu

Yunhui Liu

Chengliang Li

Yifan Zhang

Maobai Liu

Xuemei Wu

Affiliations

Soon will be listed here.

Abstract

Background: Establishing whether there is a potential relationship between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs) is crucial for public safety. This study investigated the potential association between GLP-1RAs and SSIBs by exploring the FDA Adverse Event Reporting System (FAERS) database.

Methods: A disproportionality analysis was conducted using post-marketing data from the FAERS repository (2018 Q1 to 2022 Q4). SSIB cases associated with GLP-1RAs were identified and analyzed through disproportionality analysis using the information component. The parametric distribution with a goodness-of-fit test was employed to analyze the time-to-onset, and the Ω shrinkage was used to evaluate the potential effect of co-medication on the occurrence of SSIBs.

Results: In total, 204 cases of SSIBs associated with GLP-1RAs, including semaglutide, liraglutide, dulaglutide, exenatide, and albiglutide, were identified in the FAERS database. Time-of-onset analysis revealed no consistent mechanism for the latency of SSIBs in patients receiving GLP-1RAs. The disproportionality analysis did not indicate an association between GLP-1RAs and SSIBs. Co-medication analysis revealed 81 cases with antidepressants, antipsychotics, and benzodiazepines, which may be proxies of mental health comorbidities.

Conclusions: We found no signal of disproportionate reporting of an association between GLP-1RA use and SSIBs. Clinicians need to maintain heightened vigilance on patients premedicated with neuropsychotropic drugs. This contributes to the greater acceptance of GLP-1RAs in patients with type 2 diabetes mellitus or obesity.

Citing Articles

Exploring the potential association between stimulant or atomoxetine use and suicidal or self-injurious behaviors in children with attention deficit hyperactivity disorder: real-world insights from the FAERS database.

Liu J, Xue L, Zeng F, Liu Y, Zhu Y, Zhou J Eur Child Adolesc Psychiatry. 2025; .

PMID: 40047929 DOI: 10.1007/s00787-025-02694-w.

Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis.

Bushi G, Khatib M, Rohilla S, Singh M, Uniyal N, Ballal S Diabetes Metab Res Rev. 2025; 41(2):e70037.

PMID: 39945396 PMC: 11823376. DOI: 10.1002/dmrr.70037.

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database.

Lu W, Wang S, Tang H, Yuan T, Zuo W, Liu Y Eur Psychiatry. 2025; 68(1):e20.

PMID: 39901452 PMC: 11823005. DOI: 10.1192/j.eurpsy.2024.1803.

Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study.

Bezin J, Benard-Laribiere A, Hucteau E, Tournier M, Montastruc F, Pariente A EClinicalMedicine. 2025; 80():103029.

PMID: 39844933 PMC: 11751538. DOI: 10.1016/j.eclinm.2024.103029.

Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications.

Moss L, Laudenslager M, Steffen K, Sockalingam S, Coughlin J Curr Obes Rep. 2025; 14(1):2.

PMID: 39753939 DOI: 10.1007/s13679-024-00598-5.

References

Hu Y, Bai Z, Tang Y, Liu R, Zhao B, Gong J . Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System. J Diabetes Res. 2020; 2020:3695101. PMC: 7368210. DOI: 10.1155/2020/3695101. View

Hughes J, Horowitz L, Ackerman J, Adrian M, Campo J, Bridge J . Suicide in young people: screening, risk assessment, and intervention. BMJ. 2023; 381():e070630. PMC: 11741005. DOI: 10.1136/bmj-2022-070630. View

Liu L, Chen J, Wang L, Chen C, Chen L . Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022; 13:1043789. PMC: 9770009. DOI: 10.3389/fendo.2022.1043789. View

Noren G, Hopstadius J, Bate A . Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2011; 22(1):57-69. PMC: 6331976. DOI: 10.1177/0962280211403604. View

Rubino D, Greenway F, Khalid U, ONeil P, Rosenstock J, Sorrig R . Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022; 327(2):138-150. PMC: 8753508. DOI: 10.1001/jama.2021.23619. View

Barritt 4th A, Marshman E, Noureddin M . Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Aliment Pharmacol Ther. 2022; 55(8):944-959. PMC: 9310586. DOI: 10.1111/apt.16794. View

Gliatto M, Rai A . Evaluation and treatment of patients with suicidal ideation. Am Fam Physician. 1999; 59(6):1500-6. View

Gonda X, Dome P, Serafini G, Pompili M . How to save a life: From neurobiological underpinnings to psychopharmacotherapies in the prevention of suicide. Pharmacol Ther. 2023; 244:108390. DOI: 10.1016/j.pharmthera.2023.108390. View

Ren W, Wang W, Guo Y . Analysis of Adverse Reactions of Aspirin in Prophylaxis Medication Based on FAERS Database. Comput Math Methods Med. 2022; 2022:7882277. PMC: 9162824. DOI: 10.1155/2022/7882277. View

10.

ONeil P, Birkenfeld A, McGowan B, Mosenzon O, Pedersen S, Wharton S . Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018; 392(10148):637-649. DOI: 10.1016/S0140-6736(18)31773-2. View

11.

Jastreboff A, Kushner R . New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. Annu Rev Med. 2023; 74:125-139. DOI: 10.1146/annurev-med-043021-014919. View

12.

Fusaroli M, Raschi E, Giunchi V, Menchetti M, Rimondini Giorgini R, De Ponti F . Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System. Int J Neuropsychopharmacol. 2022; 25(9):727-736. PMC: 9515127. DOI: 10.1093/ijnp/pyac031. View

13.

Noguchi Y, Tachi T, Teramachi H . Comparison of Signal Detection Algorithms Based on Frequency Statistical Model for Drug-Drug Interaction Using Spontaneous Reporting Systems. Pharm Res. 2020; 37(5):86. DOI: 10.1007/s11095-020-02801-3. View

14.

da Silva Bandeira B, Dos Santos Junior A, Dalgalarrondo P, de Azevedo R, Celeri E . Nonsuicidal self-injury in undergraduate students: a cross-sectional study and association with suicidal behavior. Psychiatry Res. 2022; 318:114917. DOI: 10.1016/j.psychres.2022.114917. View

15.

Yaribeygi H, Sathyapalan T, Sahebkar A . Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci. 2019; 234:116776. DOI: 10.1016/j.lfs.2019.116776. View

16.

Tan B, Pan X, Chew H, Goh R, Lin C, Anand V . Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes (Lond). 2023; 47(8):677-685. DOI: 10.1038/s41366-023-01321-5. View

17.

Battini V, Van Manen R, Gringeri M, Mosini G, Guarnieri G, Bombelli A . The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase. Front Pharmacol. 2023; 14:1128387. PMC: 9981969. DOI: 10.3389/fphar.2023.1128387. View

18.

Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius V . Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013; 36(10):995-1006. DOI: 10.1007/s40264-013-0061-7. View

19.

Li J, Cao J, Wei J, Geng W . Case Report: Semaglutide-associated depression: a report of two cases. Front Psychiatry. 2023; 14:1238353. PMC: 10495976. DOI: 10.3389/fpsyt.2023.1238353. View

20.

Davies M, Aroda V, Collins B, Gabbay R, Green J, Maruthur N . Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022; 45(11):2753-2786. PMC: 10008140. DOI: 10.2337/dci22-0034. View